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Summary
The BCL-2 family of apoptotic proteins encompasses
key regulators proximal to irreversible cell damage.
The BH3-only members of this family act as sentinels,
interconnecting specific death signals to the core
apoptotic pathway. Our previous data demonstrated
a role for BH3-only BID in maintaining myeloid ho-
meostasis and suppressing leukemogenesis. In the
absence of Bid, mice accumulate chromosomal aber-
rations and develop a fatal myeloproliferative disor-
der resembling chronic myelomonocytic leukemia.
Here, we describe a role for BID in preserving geno-
mic integrity that places BID at an early point in the
path to determine the fate of a cell. We show that BID
plays an unexpected role in the intra-S phase check-
point downstream of DNA damage distinct from its
proapoptotic function. We further demonstrate that
this role is mediated through BID phosphorylation by
the DNA-damage kinase ATM. These results establish
a link between proapoptotic Bid and the DNA-dam-
age response.
Introduction
The BCL-2 family of proteins is predominantly situated
upstream of irreversible cellular damage in the intrinsic
apoptotic pathway (reviewed in Danial and Korsmeyer
[2004]). Pro- as well as antiapoptotic members contrib-
ute to apoptotic susceptibility and the predisposition to
cancer. The BH3-only proapoptotic members connect
specific proximal death signals with the multidomain
proapoptotic molecules BAX and BAK that serve as an
obligate gateway to apoptotic death. The multidomain
antiapoptotic members bind and sequester BH3-only
molecules to protect from activation of BAX, BAK as
one mechanism of preventing death.
The BH3-only member BID serves the unique func-
tion of interconnecting the extrinsic death receptors for*Correspondence: sandra.zinkel@vanderbilt.edu
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4 Present address: Department of Medicine, Vanderbilt University
School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville,
Tennessee 37232.TNFα and Fas to the mitochondrial amplification loop
of the intrinsic pathway. In a resting cell, BID is pre-
dominantly cytoplasmic. Following TNFα or Fas treat-
ment, BID is cleaved by caspase 8 in an unstructured
loop, exposing a new amino terminal glycine residue,
which becomes myristoylated, facilitating its transloca-
tion to the mitochondria (Zha et al., 2000). Activated
BH3-only proteins such as caspase-truncated BID
(tBID) either directly or indirectly activate BAX and BAK,
which are required for the release of cytochrome c and
the downstream apoptotic program.
Mouse embryonic fibroblasts (MEFs) doubly deficient
in BAX and BAK are resistant to apoptosis induced by
treatment with DNA-damaging agents, such as etopo-
side and ultraviolet (UV) irradiation (Wei et al., 2001).
Several BH3-only proteins, namely Noxa and Puma
have been implicated as upstream regulators of DNA
damage-induced apoptosis. Noxa responds to p53-
dependent apoptosis following etoposide and UV-
induced DNA damage. Noxa-deficient intestinal crypt
cells but not thymocytes are resistant to high doses of
ionizing radiation (IR; Shibue et al., 2003). Puma plays a
role in thymocyte apoptosis following IR and etoposide
treatments (Villunger et al., 2003).
The role of BID in normal development and cellular
homeostasis has been characterized using mice in
which Bid has been disrupted. When challenged with
lethal doses of agonistic anti-Fas antibody, mice with-
out BID are resistant to the ensuing Fas-induced hepa-
tocellular apoptosis, indicating a critical role for a BID-
dependent mitochondrial amplification loop in this liver
cell death (Yin et al., 1999). Despite this dramatic phe-
notype, Bid−/− mice successfully complete embryonic
development and their livers appear grossly normal.
However, as they age, Bid−/− mice spontaneously de-
velop a myeloproliferative disorder that progresses to a
fatal disease resembling chronic myelomonocytic leu-
kemia (CMML). This indicates an essential role for BID
in maintaining myeloid homeostasis and suppressing
leukemogenesis (Zinkel et al., 2003).
A critical question is how BID is involved in suppress-
ing oncogenesis. While the loss of BID could theoretic-
ally reset death susceptibility in both intrinsic and ex-
trinsic pathways, it is less obvious why the absence of
BID should prove so oncogenic. A striking feature of
the BID-deficient CMML is the frequent presence of ge-
nomic instability as evidenced by chromosomal trans-
location (Zinkel et al., 2003). This suggests that BID
might also serve a role in preserving genomic integrity.
Progression to malignancy is a multistep process in
which a succession of genetic changes culminates in
phenotypic changes (Jacks and Weinberg, 2002). Main-
tenance of genomic integrity is of fundamental impor-
tance to the survival and health of an organism. DNA
is highly reactive and subject to damage by multiple
reagents including reactive oxygen species, methylat-
ing agents, both UV and IR as well as stochastic errors
that can arise during DNA replication and recombina-
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580tion. Cells respond to the presence of DNA damage by
activating cell cycle checkpoints and repair mecha-
nisms, and ultimately the damaged cell is eliminated
through apoptosis.
The cellular response to DNA damage varies by cell
type. For example, fibroblasts are relatively resistant to
DNA damage-induced apoptosis; they prevent prolifer-
ation of mutations by entering into long-term G1 or G2
arrest (Baus et al., 2003; Di Leonardo et al., 1994).
Hematopoietic cells are primed to undergo apoptosis
following treatment with DNA-damaging agents. The
signals that govern whether a cell initiates DNA repair,
enters cell cycle arrest, or undergoes apoptosis and the
means by which the cell integrates information from
these pathways are not yet understood. Three DNA re-
pair kinases have been identified. ATM (Ataxia-telangi-
ectasia mutated), ATR (ATM and RAD3-related) and
DNA-PK (reviewed in Sancar et al. [2004]). The specific
DNA-damage signals that activate ATM or ATR are not
well defined in part due to the multiple distinct DNA
lesions generated by signals such as IR, UV, and alkyl-
ating agents (Nyberg et al., 2002). ATM has been re-
ported to respond primarily to agents such as IR that
generate double-strand breaks, while ATR appears to
respond to agents inducing multiple types of DNA dam-
age (Zhou and Elledge, 2000). Fibroblasts deficient in
ATM demonstrate increased sensitivity to IR but not to
UV, alkylating agents, or inhibitors of DNA replication
(Banin et al., 1998; Canman et al., 1998; Zhou and
Elledge, 2000). Cells expressing kinase-inactive ATR
demonstrate increased sensitivity to IR, UV, cisplatin,
and methyl methane sulfonate (Cliby et al., 1998). ATR
is required for cell cycle regulation and phosphorylation
of downstream kinases such as Chk1 in response to
replication blocks and UV irradiation (Guo et al., 2000).
Both ATM and ATR relocalize to nuclear foci following
DNA damage (Andegeko et al., 2001; Tibbetts et al.,
2000), and both kinases display a common substrate
preference (Kim et al., 1999; Manke et al., 2003; O’Neill
et al., 2000).
Bid−/− primary MEFs have been shown to be some-
what resistant to chemotherapeutic drugs 5-fluoroura-
cil (5-FU) and adriamycin (Sax et al., 2002), but not to
UVC or etoposide (Wei et al., 2001). Thus, BID does
not appear to play a prominent role in the apoptotic
response downstream of DNA damage in fibroblasts.
However, Bid−/− mice progress to a high incidence of
myeloid malignancy with considerable genomic insta-
bility in that cell type. Wild-type hematopoietic cells
have a marked propensity for apoptosis in response to
DNA damage; yet in the absence of BID, myeloid cells
accumulate mutations, resist apoptosis, and display
aspects of unchecked proliferation. This suggests that
BID may itself play a role in DNA repair, in cell cycle
checkpoint response, or in integrating apoptosis and
the DNA repair response. In this study, we describe a
novel role for BID in preserving genomic integrity that
places BID at an early point in the path to determine
the fate of a cell. We show that BID plays an unex-
pected role in the intra-S phase checkpoint down-
stream of DNA damage. We further demonstrate that
this role is mediated through BID phosphorylation by
the DNA-damage kinase ATM.
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id−/− Myeloid Progenitor Cells (MPCs) Display
ncreased “Chromatid Type” Chromosomal
nstability Following Mitomycin C Treatment
id-deficient CMMLs are clonal and display chromo-
omal aberrations. SKY analysis of the Bid−/− leukemia
evealed chromosomal translocations and duplications
Zinkel et al., 2003). In addition, array CGH studies of
ultiple tumors revealed recurrent sites of chromo-
omal amplification (data not shown). Absence of pro-
poptotic BID may enable the accumulation of cells
ith genetic lesions and foster their survival. Alterna-
ively, genomic instability may be intrinsic to Bid−/−
ells, implicating a role for BID in a DNA-damage path-
ay. To investigate the function of BID in myeloid cells,
e generated Hox11-immortalized premalignant my-
loid progenitor cell lines (MPCs) from Bid+/+ and
id−/− genotypes. Doses of mitomycin c that had little
ffect on Bid+/+ MPCs displayed a marked increase in
hromosomal instability in Bid−/− MPCs. Of note, meta-
hase spreads from mitomycin c-treated Bid−/− MPCs
isplayed tri- and quadriradial chromosomal figures
Figure 1A), quantifiable by an increase in the number
f breaks per cell (Figure 1B). These abnormal chromo-
omal structures represent “chromatid type” errors re-
ulting from improperly repaired DNA damage accrued
uring S phase of the cell cycle (Scully et al., 2000) and
re characteristic of cells with a defect in DNA repair,
uch as those in Fanconi anemia (D’Andrea, 2003),
loom’s syndrome (Langland et al., 2002; Wu et al.,
001), and the hereditary breast and ovarian cancer
yndromes involving BRCA1 (Scully and Livingston,
000). Activated peripheral T cells isolated from Bid−/−
ice also display increased chromosomal instability
ollowing mitomycin c treatment (Figures 1C and 1D),
ndicating that this increased chromosomal instability
s a general feature of Bid deficiency, although it is more
ronounced in myeloid cells.
id−/− MPCs Display Increased Sensitivity
o DNA-Damaging Agents
ells defective in DNA repair exhibit increased sensitiv-
ty to DNA-damaging agents (D’Andrea, 2003; Frei and
asser, 2000; Stewart et al., 1997). Following treatment
ith hydroxyurea or mitomycin c, agents that induce
NA damage through replicative stress, Hox11-immor-
alized Bid−/− MPCs, display increased cell death (Fig-
re 2A). Bid−/− primary MPCs (see Figure S1 in the Sup-
lemental Data available with this article online) and
id−/− primary activated T cells (Figures 2B and 2C) dis-
lay similarly increased mitomycin c sensitivity, con-
irming that the increased death response to replicative
tress is not due to Hox11 immortalization and is a gen-
ral feature of Bid deficiency. In contrast, there was no
ignificant difference in viability in response to treat-
ent with UV or IR; treatment with etoposide, an inhibi-
or of topoisomerase 2, resulted in a modest protection
f Bid−/− MPCs from apoptosis (Figure 2A). Hydroxy-
rea washout experiments also revealed decreased vi-
bility of Bid−/− MPCs relative to Bid+/+ MPCs (Figure
B). Interestingly, we find a small but significant de-
A Role for BID in the DNA-Damage Response
581Figure 1. Bid−/− Cells Demonstrate Increased Chromosomal Damage in Response to Mitomycin C Treatment
The error bars represent the standard deviation of the data obtained from 50 metaphase spreads.
(A) Metaphase spreads of wild-type and Bid−/− MPCs after 24 hr of treatment with mitomycin c (100 nM). Cells were arrested in metaphase
with 0.1 mg/ml of colchicine, fixed, and visualized by Giemsa staining. The yellow arrow designates a quadriradial, and the black arrow
designates a chromosomal break.
(B) Quantification of the number of chromosomal breaks per cell evaluated in 50 metaphase spreads.
(C) Metaphase spreads of wild-type and Bid−/− primary activated T cells after 24 hr of treatment with mitomycin c (100 nM). Cells and
chromosomes were prepared as in (A).
(D) Quantification of the number of chromosomal breaks per cell evaluated in 50 metaphase spreads.crease in cell viability of Bid−/− primary activated T cells
in response to IR (data not shown), a cell type that is
less dependent upon the BID-mediated mitochondrial
amplification loop for death (Scaffidi et al., 1998). The
above data demonstrate a surprising sensitivity of cells
deficient for proapoptotic BID in response to agents in-
ducing DNA damage through replicative stress, sug-
gesting a possible role for BID in this pathway that is
distinct from its proapoptotic role.
BID−/− MPCs Fail to Accumulate in S Phase
Following Replicative Stress
We next examined the cell cycle status of MPCs to
characterize the role of Bid following replicative stress.
As evidenced by propidium iodide staining, untreated
Bid+/+ and Bid−/− MPCs display an identical cell cycle
profile. Following treatment with aphidicolin, Bid+/+
MPCs but not Bid−/− MPCs arrest and accumulate in S
phase (Figures 3Aa and 3Ab), suggesting either a de-
fect in an S phase checkpoint, a failure of Bid−/− MPCs
to progress from G1 to S phase, or death of Bid−/−
MPCs in S phase. The increase in Bid−/− cells possess-
ing <2N DNA content following aphidicolin treatment
(Figure 3A) suggests that these Bid−/− cells undergo in-
creased apoptosis. The percentage of cells in S phase
from multiple independent experiments is presented inFigure S3. To further investigate the fate of S phase
cells following replicative stress, we labeled S phase
cells with BrDU immediately prior to treatment with hy-
droxyurea, (see Figure S4 for a schematic of the experi-
mental design). After 2 hr of hydroxyurea treatment,
cells were washed, and cell cycle progression of BrDU-
positive cells was monitored by flow cytometry. The
data point at time T0 was taken at the time of hydroxy-
urea washout, and the gates indicate early S phase and
late S/G2 as cells initially in G1 are not labeled with
BrDU and thus are not included in the analysis. Immedi-
ately following hydroxyurea treatment, BrDU+ cells from
Bid+/+ and Bid−/− display a similar cell cycle distribution
(Figure 3B). By contrast, while at 6 hr Bid+/+ cells dis-
play some progression from early to late S phase, Bid−/−
cells display a significant decrease in the number of
cells in late S phase, along with an increase in cells
with <2N DNA content. These data are consistent either
with increased progression of Bid−/− cells through S
phase relative to Bid+/+ cells, or increased death of
Bid−/− cells in S phase. Taken together with the in-
creased death seen in Bid−/− primary T cells at 6 hr
after hydroxyurea treatment (Figure 2B), these data are
consistent with death of Bid−/− cells progressing
through S phase.
To verify that this S phase phenotype is attributable
to the absence of BID, we stably transduced Bid−/−
Cell
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BID functions downstream of specific DNA-damage signals in MPCs. The error bars represent the standard deviation of data points from
three independent experiments.
(A) Dose-response/survival curves of Bid−/− MPCs in response to stimuli inducing DNA damage and replicative stress. Wild-type and Bid−/−
MPCs were evaluated for survival by Trypan blue exclusion following 24 hr of treatment with the indicated doses of hydroxyurea, mitomycin
c, ultraviolet light, ionizing radiation, and etoposide.
(B) Panel 1: time course of survival of Bid+/+ and Bid−/− MPCs treated for 2 hr with 200 M hydroxyurea. Cells were washed and evaluated
for survival by Trypan blue exclusion at the indicated time points. Panel 2: time course of survival of Bid+/+ and Bid−/− activated T cells treated
for two hours with 200 M hydroxyurea. Cells were washed and evaluated as above. The percentage of antigen-specific activated CD8+ T
cells in the cultures at the time of analysis is indicated in Figure S2.
(C) Dose-response/survival curves of Bid+/+ and Bid−/− activated T cells following mitomycin c treatment at the indicated doses as in (A).MPCs with recombinant retrovirus (Figure 3D). When
wild-type BID is reexpressed at the endogenous level,
cells accumulate at S phase following aphidicolin treat-
ment (Figure 3C), confirming that the absence of BID is
the cause of the S phase defect in Bid−/− MPCs.
A Functional BID BH3-Domain Is Not Required
to Rescue S Phase Accumulation
The death function of proapoptotic BCL-2 family mem-
bers is localized to the BH3 domain. To determine
whether an intact BH3 domain is required for the BID-
deficient S phase defect, Bid−/− MPCs were transduced
with BID harboring various apoptosis-inactivating mu-
tations in the BH3 domain. (Wang et al., 1996) Surpris-
ingly, expression of endogenous levels of BID with mu-
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pant BH3 domains restores S phase accumulation of
id−/− MPCs following aphidicolin treatment (Figures
A and 4C). Furthermore, expression of either wild-type
ID or BID with mutant BH3 domains protects Bid−/−
PCs from death in response to mitomycin c treat-
ent, at a level comparable to that seen in Bid+/+ MPCs
Figure 4B). Therefore, a region of BID distinct from its
roapoptotic BH3 domain mediates the BID’s role
ownstream of DNA damage induced by replicative
tress.
ID Localizes to the Nucleus Following
NA Damage
ince signaling proteins involved in cell cycle check-
oints or DNA-damage response often function in the
A Role for BID in the DNA-Damage Response
583Figure 3. Bid−/− MPCs Fail to Accumulate in S Phase Following Treatment with Aphidicolin, Suggesting Defects in the S Phase Checkpoint
(A) Cell cycle analysis (propidium iodide staining) of Bid+/+ and Bid−/− MPCs was compared in cells left untreated or following 18–24 hr of
treatment with aphidicolin (0.1 M).
(B) Increased death of S phase cells in Bid−/−-activated T cells treated with hydroxyurea. Bid+/+ and Bid−/− S phase cells were labeled with
BrDU for 45 min (Figure S4). After 2 hr of hydroxyurea treatment, cells were washed, and progression of BrDU-positive cells through the cell
cycle was monitored by flow cytometry (top panel indicates the gating used for analysis). The data point at time T0 was taken at the time of
hydroxyurea washout, and the gates indicate early S phase and late S/G2. Cells initially in G1 are not labeled with BrDU and thus are not
included in the analysis.
(C) Reintroduction of wild-type BID by retroviral transduction restores the ability of MPCs to accumulate in S phase following aphidicolin
treatment.
(D) Reintroduction of wild-type Bid protein in Bid−/− MPCs via MSCVBID retroviral transduction results in expression similar to endogenous
levels.nucleus, we evaluated the subcellular localization of
BID. Following treatment of wild-type MEFs with hy-
droxyurea or etoposide, BID localizes to the nuclei in
the majority of cells (Figure 5A). Following IR treatment,
BID is seen both in the nuclei and in the mitochondria
(Figure 5A). Interestingly, nuclear BID is seen in approxi-
mately 14% of untreated cells, perhaps suggesting a
role for Bid in the normal cell cycle. Although the level
of tagged BID protein seen by Western blot analysis is
modestly increased relative to endogenous BID levels
in MEFs, there is no increase following treatment with
DNA-damaging agents (Figure S5), suggesting that
BID’s change in subcellular localization cannot be ac-
counted for by a change in protein level. Furthermore,
subcellular fractionation of endogenous levels of BID in
MPCs demonstrates an increase in BID primarily in the
chromatin fraction of the nucleus following hydroxyureatreatment (Figure 5C). The apparent discrepancy in the
percentage of nuclear BID after damage observed in
subcellular fractionation versus immunofluorescence
may be due to suboptimal recovery of BID from chro-
matin or loss of nuclear BID to the cytosolic fraction
during fractionation. The distinct subcellular localiza-
tion of BID following DNA damage suggests that the
distinct functions for BID may be regulated at least in
part by BID’s location in the cell.
BID Is Phosphorylated Following Treatment
with DNA-Damaging Agents
ATM, ATR, and DNA-PKcs (DNA-dependent protein ki-
nase) are known to be involved in the DNA repair path-
way (Reviewed in Sancar et al. [2004]). All three kinases
display a substrate preference for serine or threonine
followed by glutamine in a +1 position (Kim et al., 1999;
Cell
584Figure 4. A Functional BID BH3 Domain Is
Not Required to Restore S Phase Accumula-
tion of Bid−/− MPCs Following Aphidicolin
Treatment
(A) BID protein harboring apoptosis-inactiva-
ting mutations in the BH3 domain was intro-
duced into Bid−/− MPCs by retroviral trans-
duction. Cell cycle profiles were analyzed by
PI staining following 18 hr of aphidicolin
treatment.
(B) Bid−/− MPCs transduced either with wild-
type BID or BID with the apoptosis-inactive
BH3 domain mutations regain normal resis-
tance to mitomycin c treatment. Viability fol-
lowing treatment with increasing doses of
mitomycin c after 24 hr was monitored by
Trypan blue exclusion.
(C) BID and BID BH3 mutants were ex-
pressed equally in the cell lines generated
for use in this experiment as monitored by
immunoblotting with anti-BID antisera.Manke et al., 2003; O’Neill et al., 2000). BID has at least
two ATM/ATR/DNA-PKcs consensus phosphorylation
sites at residues S61 and S78 (Figure 6A), with S78 con-
served between mouse and human BID. BID is phos-
phorylated in a dose-dependent manner at serines 61/
64 and 78 as well as serine 61 following treatment with
hydroxyurea, aphidicolin, and mitomycin c, all of which
cause DNA damage via replicative stress (Figure 6B
and Figure S6). BID is also phosphorylated following
treatments with agents inducing DNA strand breaks
such as etoposide, UV, and IR (Figure 6C). We used
antibodies raised against phosphopeptides of the re-
gions surrounding residues 61/64 (Desagher et al.,
1999) and 61 and 78 (Dr. Atan Gross [Kamer et al., 2005,
this issue of Cell] in collaboration with the Bethyl
Laboratories, Inc., Montgomery, Texas), and confirmed
the specificity of the phosphoantibodies using extracts
from Bid−/− cells (Figure S6). The above data is consis-
tent with constitutive phosphorylation of Bid on serine
64, with stimulation of phosphorylation on serine 61 in
response to DNA damage. Thus, in response to DNA
damage, BID is phosphorylated at the ATM/ATR/DNA-
PKcs consensus sites, suggesting that its role in this
pathway may be regulated by these DNA repair ki-
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ortmannin is a fungal metabolite that inhibits the ki-
ase activities of ATM, ATR, and DNA-PKcs (Sarkaria et
l., 1998). BID phosphorylation in response to hydroxy-
rea treatment is decreased in the presence of levels
f wortmannin known to inhibit ATM and DNA-PKcs,
ut only partially inhibit ATR (Figure 6D, lane 4 versus
ane 6). Hydroxyurea-induced BID phosphorylation is
ot decreased in the presence of the PI3 kinase inhibi-
or LY294002 (Figure 6D, lane 5). Although LY294002
as been reported to inhibit DNA-PKcs, but not ATM or
TR (Stiff et al., 2004), significantly higher doses (200
M) are required to produce minimal inhibition of hy-
roxyurea-induced Bid phosphorylation (Figure S7B).
he above data are consistent with a minimal role for
I3 kinases in BID phosphorylation downstream of DNA
amage and suggest that BID may be a substrate of
ne of the DNA-damage kinases.
Since the casein kinase family has been reported to
hosphorylate BID, (Desagher et al., 1999), we also
ested specific inhibitors of these kinases. Inhibitors of
ither casein kinase 1 (CKI-7) or casein kinase 2 (TBB)
o not abolish hydroxyurea-induced phosphorylation of
ID at serine 61 or 78 (Figure S7A, lanes 4 and 3, re-spectively, versus lane 2), suggesting that DNA dam-
A Role for BID in the DNA-Damage Response
585Figure 5. BID Translocates to the Nucleus Following DNA Damage
(A) Immunofluorescence confocal imaging of HA-tagged BID in mouse embryonic fibroblasts at 2 hr following (a) no treatment (b) hydroxyurea
(1 mM), (c) etoposide (20 M), and (d) Ionizing radiation (10 Gy).
(B) Percent of cells with >50% nuclear localization by confocal microscopy following 2 hr of treatment with DNA-damaging agents.
(C) Subcellular fractionation of MPCs at 2 hr following hydroxyurea treatment (1 mM). BID is found in the insoluble chromatin fraction
following hydroxyurea.age-induced BID phosphorylation may be mediated by
a kinase distinct from the casein kinases.
BID Is a Substrate of ATM/ATR
To further elucidate the kinase responsible for regula-
tion of BID phosphorylation, we evaluated a series of
MEFs deficient for the DNA repair kinases ATM, ATR,
and DNA-PKcs. In the absence of ATM, phosphoryla-
tion of BID at serines 61/64 and 78 in response to hy-
droxyurea, UV light, and ionizing radiation is nearly
completely abrogated (Figure 6E, lanes 6, 7, and 8). In
contrast, BID is phosphorylated at serines 61/64 and
78 in response to DNA damage induced by hydroxyurea
and IR, even in cells partially deficient for ATR or defi-
cient for DNA-PKcs (Figure 6H, lane 4, and Figure S8,
lane 4). These data suggest that ATM is the major ki-
nase mediating the phosphorylation of BID in response
to IR, UV, and hydroxyurea-induced DNA damage. ATM
has been reported to respond primarily to agents such
as IR that generate double-strand breaks, while ATR
appears to respond to agents inducing multiple types
of DNA damage (Zhou and Elledge, 2000). ATM is acti-
vated by these types of damage under our conditions,
as it is autophosphorylated on serine 1981 (Bakkenist
and Kastan, 2003), and a downstream substrate of
ATM, Chk2, is also activated (Figure 6F). Of note, we
cannot rule out a role for ATR in BID phosphoryla-
tion as the Cre-mediated excision of ATR (Brown and
Baltimore, 2003; Stiff et al., 2004), did not completely
eliminate ATR expression (Figure 6H). In addition, accu-
mulation of double-strand breaks in the resultant ATR-deficient cells may lead to activation of ATM kinase ac-
tivity (Brown and Baltimore, 2003; Cha and Kleckner,
2002; Lopes et al., 2001) or activation of a compensa-
tory kinase may result in nonspecific phosphorylation
of BID. ATR is active in our ATM null MEFs, since the
ATR substrate Chk1 is phosphorylated in response to
the HU and UV treatment conditions used (Figure 6G).
Interestingly, full-length CHK1 appears to be signifi-
cantly decreased in myeloid cells, and we note the
presence of a smaller form of CHK1, raising the possi-
bility that the signaling pathway downstream of UV in
myeloid cells may be distinct and may account for the
similar UV sensitivity in Bid−/− and Bid+/+ cells. Never-
theless, neither ATR nor DNA-PKcs compensates for
the loss of ATM.
To determine if ATM and/or ATR could directly phos-
phorylate BID, we performed in vitro kinase assays
using FLAG-tagged ATM and ATR and recombinant
mouse BID. Wild-type but not kinase-inactive human
ATM and ATR phosphorylate BID in vitro (Figure 6I,
lanes 2 and 4 versus lanes 3 and 5), suggesting that
BID can serve as a substrate of both ATM and ATR.
Taken together with the above genetic studies, ATM or
a kinase downstream of ATM is strongly implicated as
the major kinase-mediating BID phosphorylation fol-
lowing DNA damage.
Bid−/− MPCs Have an Intra-S Phase
Checkpoint Defect
To further dissect the cell cycle S phase aberration in
Bid−/− MPCs, we tested the ability of these MPCs to
Cell
586Figure 6. Bid Is a Substrate of ATM Downstream of DNA Damage
Similar results were obtained for residues 61/64 and 78 but for some panels only blots for either 61/64 or 78 are shown.
(A) Sequence alignment of mouse and human BID. Potential ATM/ATR consensus phosphorylation sites at serines 61and 78 are underlined.
Serine residues conserved between mouse and human are indicated in red. The caspase 8 cleavage site (C8) and BH3 domain are indicated.
(B) BID is phosphorylated on serines 61 and 78 in a dose-dependent manner in response to hydroxyurea, aphidicolin, and mitomycin c
treatment. Wild-type MPCs were incubated for 3 hr with 1 mM and 10 mM hydroxyurea, 1 M and 10 M aphidicolin, 1 M and 10 M (30
M, or three times the previous dose, in right panel) mitomycin c. The cells were harvested and BID was immunoprecipitated, followed by
immunoblotting with anti-phospho BIDS61/64 or anti-phospho BIDS78. The blots were then stripped and blotted for total BID levels.
(C) BID is phosphorylated on serines 61and 78 in response to treatment with hydroxyurea, IR, and etoposide. Wild-type MPCs were incubated
for 3 hr either with 1 mM hydroxyurea, 10 M etoposide, 10 J/m2 UV light, or with 5 Gy or 10 Gy of ionizing radiation for the times indicated.
To monitor BID phosphorylation, samples were subjected to BID immunoprecipitation and immunoblotting with anti-phospho BIDS61/64 or
anti-phospho BIDS78 as in (B).
(D) Hydroxyurea-induced phosphorylation of BID is abolished on serine 61(and serine 78, see Figure S6) following treatment with wortmannin
but not LY294002. Wild-type MPCs were pretreated with wortmannin (10 M; Sigma) or LY 294002 (50 M; Sigma) for 30 min prior to the
addition of 10 mM hydroxyurea for 2 hr.
(E) DNA damage-induced phosphorylation of Bid is abolished in ATM null cells. wt or ATM-deficient MEFs were treated with 10 mM hydroxy-
urea for 2 hr, 10 Gy IR for 1 hr, or 10 J/m2 UV for 2 hr. Cells were harvested and lysates were analyzed for Bid phosphorylation as in (B).
SV40-transformed MEFs were used in the experiment shown, but similar results were seen using primary MEFs.
A Role for BID in the DNA-Damage Response
587these myeloid leukemias suggests a role for BID in pre-
(F) ATM is activated by DNA damage under the conditions used as indicated by immunoblotting with Anti-phosphoATMS1981. In addition, a
downstream substrate of ATM, Chk2, is also activated by the DNA-damage treatments used. Chk2 phosphorylation is visualized by an upward
shift in mobility using Anti-Chk2 antisera (BD Biosciences, monoclonal).
(G) ATR is active in the ATM−/− MEFs, however, does not compensate for the absence of ATM. ATR activity was assessed by monitoring
phosphorylation of Chk1, a downstream substrate of ATR, in response to DNA damage. Chk1 phosphorylation on serine 345 was induced by
DNA damage in both wt and ATM knockout MEFs. Chk1 phosphorylation also induces a mobility shift and was monitored using a Chk1
antibody (Santa Cruz, monoclonal).
(H) DNA damage-induced phosphorylation is not abolished in ATR flox/− cells. ATR was deleted using retrovirally introduced Cre recombinase.
wt MEFs were also infected and used as a control. After 24 hr, cells were treated with 10 mM hydroxyurea for 2 hr and analyzed for Bid
phosphorylation as in (B). Efficiency of ATR deletion was monitored by immunoblotting using anti-ATR antisera (Serotec).
(I) Bid is a substrate for ATM and ATR in vitro. FLAG-tagged hATR or hATM or FLAG-tagged kinase-inactive hATR or hATM was overexpressed
in 293T cells, immunoprecipitated with anti-FLAG M2 agarose, washed several times, and then incubated in the presence of recombinant
mBID and γ32PATP. Reactions were separated on 12% SDS-PAGE, and phosphorylated Bid was visualized by autoradiography. Levels of
FLAG-ATM and FLAG-ATR were monitored by immunoblotting with anti-FLAG M2 antisera and levels and purity of recombinant mBid were
visualized by Coomassie staining.
sensitivity to DNA-damaging agents (D’Andrea, 2003;undergo replication arrest following treatment with
either IR using a classic radioresistant DNA synthesis
(RDS) assay, or modifying the RDS assay to assess rep-
lication arrest after treatment with mitomycin c. Bid+/+
MPCs but not Bid−/− MPCs undergo replication arrest
in response to both mitomycin c and IR treatment (Fig-
ures 7A and 7C, respectively). Bid−/−-activated T cells
(Figure 7D) display a similar abrogation of the IR-induced
replication arrest, confirming that this intra-S phase
checkpoint defect is a general feature of BID deficiency.
Wild-type BID as well as BH3 mutant BID transduced
into Bid−/− MPCs restored replication arrest following
IR (Figure 7C, green and yellow bars, respectively), pro-
viding further evidence that the checkpoint defect is
mediated by BID. Taken together, the above data pro-
vide strong evidence that BID plays a role in the intra-S
phase checkpoint and that this role is mediated by a
region of BID distinct from its prodeath domain.
The S Phase Role of BID Is Mediated by
Phosphorylation at Position 78
Endogenous levels of BID S78A transduced into Bid−/−
MPCs are unable to restore aphidicolin-induced S
phase arrest (Figure 7B), suggesting that BID phos-
phorylation at serine 78 may function at the S phase
checkpoint. In addition, Bid−/− MPCs transduced with
a BID S78A mutant remain defective in IR-induced S
phase arrest (Figure 7C, blue bar). Bid−/− MPCs trans-
duced with the BID S61A mutant exhibit excessive apo-
ptosis, consistent with the published report from De-
sagher et al. (1999) (data not shown). The cell cycle role
of BID serine 61 in response to replicative stress will
thus require additional study. The above results strongly
suggest that BID’s S phase role downstream of DNA
damage is mediated by phosphorylation of the ATM/
ATR consensus site at position 78.
Discussion
BID deficiency, a proximal defect in the death-receptor
pathway, results in altered myeloid homeostasis. In the
absence of BID, myeloid cells resist apoptosis, accu-
mulate mutations, and display aspects of unchecked
proliferation, culminating in a clonal malignancy of the
myeloid lineage resembling human CMML (Zinkel et al.,
2003). The surprising degree of genomic instability ofserving genomic integrity that places BID at an early
point in the path to determine the fate of a cell. Here,
we show that BID plays an unexpected role in the intra-
S phase checkpoint downstream of DNA damage that
is distinct from its proapoptotic role. ATM/ATR-medi-
ated BID phosphorylation at serine 78 is required for
the IR-mediated intra-S phase checkpoint. An intact
BH3 domain, which is required for apoptosis, is not re-
quired for the BID-mediated S phase effects or the in-
creased sensitivity to replicative stress, suggesting that
the role of BID in the DNA-damage response is distinct
from its proapoptotic function. Furthermore, like ATM
and ATR (Dart et al., 2004; Gately et al., 1998), BID lo-
calizes to the chromatin fraction of the nucleus follow-
ing treatment with DNA-damaging agents.
One interesting feature of Bid−/− myeloid cells is their
apparent lack of sensitivity to IR or UV irradiation. Our
data strongly suggest that ATM is a major upstream
kinase of BID following DNA damage, indicating that
this is an important signaling pathway. Bid-deficient
hematopoietic cells display a profound defect in the in-
tra-S phase checkpoint in response to IR, demonstrat-
ing a biological role for BID downstream of ATM signal-
ing. Of note, there is precedence for important signaling
pathways that do not result in a phenotype with respect
to viability. For example, ATR mediates phosphorylation
and monoubiquitination of Fanconi D2, (Andreassen et
al., 2004) but fibroblasts deficient in FANCD2 do not
display significantly increased sensitivity to UV (Kalb et
al., 2004). Given the importance of apoptosis to mainte-
nance of homeostasis in hematopoietic cells, it is pos-
sible that in the absence of BID, another BCL-2 family
member compensates for the loss of BID’s apoptotic
function. Following IR treatment, BID is localized both
in the mitochondria and in the nucleus. It is also intrigu-
ing to envision that both the proapoptotic function of
BID and its role downstream of DNA damage may be
operative simultaneously and that the fate of the cell to
proliferate or to die may be balanced by these two
functions.
Bid−/− myeloid progenitor cells have a phenotype re-
sembling that found in cells with chromosomal instabil-
ity syndromes such as Fanconi anemia, Bloom’s syn-
drome, and the hereditary breast and ovarian cancer
syndromes involving BRCA1. These phenotypes in-
clude the presence of tri- and quadriradial chromo-
somes, intra-S phase checkpoint defects, and hyper-
Cell
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(A) Bid−/− MPCs display an S phase checkpoint defect following mitomycin c treatment. Bid+/+ and Bid−/− MPCs were labeled for 24 hr with
14C thymidine, treated with 3 M mitomycin c for 4 hr, and incubated with 3H thymidine for 30 min. The ratio of 3H thymidine to 14C thymidine
was normalized to the appropriate untreated control to determine the relative amount of DNA synthesis. The error bars in (A), (C), and (D)
represent the standard deviation of data points from three independent experiments.
(B) Bid−/− MPCs expressing the BID S78A mutant fail to restore S phase accumulation in BID null MPCs following aphidicolin treatment. Bid−/−
MPCs into which either wild-type BID or BID S78A was introduced by retroviral transduction were incubated with 0.1 M aphidicolin for 18–
24 hr and DNA content was analyzed by PI staining and flow cytometry.
(C) Bid−/− MPCs expressing wild-type BID or the BH3 mutant BIDmIII.4 display an intact intra-S phase checkpoint following IR, whereas Bid−/−
MPCs as well as Bid−/− MPCs expressing the BID S78A mutant display a defective intra-S phase checkpoint following IR treatment. Cells
were labeled as above. The ratio of 3H thymidine to 14C thymidine was normalized to the appropriate untreated control to determine the
relative amount of DNA synthesis.
(D) Bid−/− primary activated T cells display a defective intra-S phase checkpoint following IR treatment. Cells were labeled and analyzed as
in (C).
(E) Model for dual roles of BID. Following death-receptor-induced apoptotic signals, BID is posttranslationally modified by caspase cleavage
and myristoylation and translocates to the mitochondrion to activate the downstream apoptotic program. BID has a distinct role downstream
of DNA damage. Following treatment with agents inducing DNA damage such as mitomycin c, IR, and hydroxyurea, BID accumulates in the
nucleus and is phosphorylated by the DNA-damage kinase ATM. This phosphorylation is required for a downstream function in cell cycle
checkpoint control.
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et al., 2001). The defective proteins in these syndromes
have been shown to play a role in the repair of DNA
damage. These similarities in phenotype warrant future
studies to determine if BID may play a role in DNA
repair.
How might BID exert its effect in response to DNA
damage? The cell cycle checkpoint machinery is local-
ized in the nucleus in multiprotein complexes. The loca-
tion of BID in the nucleus following DNA damage as
well as its functional interaction with ATM/ATR suggest
that BID could be a member of such a multiprotein
complex. The amino acid sequence of BID does not
have any obvious nuclear localization signals, suggest-
ing that BID is transported into the nucleus as part of
a protein complex that moves in response to DNA dam-
age. BID may play a role to stabilize the complex or it
may help orient members of the complex in order to
facilitate subsequent enzymatic steps. Finally, it is pos-
sible that BID may possess an additional enzymatic
function integral to checkpoint execution.
BID is phosphorylated following DNA damage in fi-
broblasts and hematopoietic cells. The intra-S phase
checkpoint, important for maintaining genomic stability,
is mediated by BID phosphorylation. Yet in vivo, Bid
deficiency manifests as altered homeostasis and leuke-
mogenesis with considerable genomic instability, spe-
cifically in the myeloid lineage. Hematopoietic cells are
particularly sensitive to low to moderate levels of geno-
toxic stress relative to other cell types, relying on apo-
ptosis to prevent accumulation of mutations. Following
DNA damage, cells initiate a complex series of re-
sponses, including the activation of checkpoints or trig-
gering apoptosis. In order to maintain homeostasis,
these pathways must be carefully balanced and coordi-
nated in the hematopoietic lineage. BID, with its dual
function in both apoptosis and the intra-S phase check-
point, is well positioned to serve as a mediator between
these two pathways.
Experimental Procedures
Cell Lines
Hox11 immortalization of MPCs was as follows: after sacrifice by
CO2 asphyxiation, bone marrows were harvested from six Bid−/−
mice (generation F9 on a C57Bl6 background) as well as 6 age
and sex-matched wild-type mice. MPCs were isolated by lineage
depletion (Lin: CD3, Gr-1, B220, ter119) followed by positive selec-
tion of Sca-1+ cells by magnetic beads (Miltenyi). These cells were
cocultured with irradiated (30 Gy) 90% to 100% confluent NIH 3T3
hph-HOX11 retroviral producer cells in infection medium (IMDM,
20% fetal calf serum [FCS] 100 U/ml penicillin-streptomycin, 2 mM
glutamine, 10 ng/ml IL-3, 20 ng/ml stem cell factor [SCF], 10 ng/ml
granulocyte-macrophage colony stimulating factor [GM-CSF], and
2 ng/ml granulocyte colony stimulating factor [G-CSF]) for 3 days
at 37°C in 5% CO2 (Hawley et al., 1994). The cells growing in sus-
pension were expanded in IMDM 20% FCS, 100 U/ml penicillin-
streptomycin, 2 mM glutamine with 10% conditioned medium from
WEHI cells as a source of IL-3. Cells were immortalized on two
separate occasions. Cells from these two separate preparations
behave similarly, and data from the two preparations have been
pooled for presentation.
ATR was deleted from ATR flox/− and control MEFs using retrovi-
ral transduction with pMIG-CRE-GFP and ATR levels verified by
immunoblotting. DNA-PKcs−/− and control MEFs were cultured
using standard methods. ATM (129S6/SvEvTac-Atmtm1Awb/J) mice
(Jackson Laboratory) were used to prepare MEFs by routine
methods.Cell Death Assays
Hox11-immortalized MPCs were treated with a range of doses of
hydroxyurea (10 M–1 mM), mitomycin c (1 nM–1.5 M), aphidi-
colin, IR (1 Gy–10 Gy), etoposide (0.2 M–100 M) and UV (2–100
J/M2). Cell viability was measured after 24 hr by Trypan blue
staining.
MPCs were isolated by lineage depletion followed by positive
selection of Sca-1+ cells by magnetic beads (Miltenyi). Cells were
cultured in IMDM, 20% fetal calf serum (FCS), 100 U/ml penicillin-
streptomycin, 2 mM glutamine, 10 ng/ml IL-3, 20 ng/ml stem cell
factor (SCF), 10 ng/ml GM-CSF, and 2 ng/ml G-CSF for 3 days at
37°C in 5% CO2 and then treated with DNA-damaging agents as
above.
Populations enriched in primary peripheral CD8+ T cells were ob-
tained from Bid−/− mice, which have been bred into an H-Y T cell
receptor transgenic mouse model (Kisielow et al., 1988). After sac-
rifice by CO2 asphyxiation, spleens were harvested from Bid−/− as
well as Bid+/+ mice; splenocytes were isolated and incubated in
RPMI + IL-2 + 0.1 M antigenic peptide (HY) for 3 days and treated
with mitomycin c and hydroxyurea, and cell viability was measured
after 24 hr as above.
Metaphase Spreads
Bid+/+ and Bid−/− MPCs were treated with 100 M mitomycin c for
24 hr. Cells were fixed and metaphase spreads prepared by stan-
dard methods. Fifty metaphases each from Bid+/+ and from Bid−/−
MPCs were scored for chromosomal damage per metaphase as
follows: each chromosome break was given a score of +1, and
each triradial or quadriradial form was given a score of +2
Cell Cycle Analysis
One million cells were resuspended in 200 l Krishan’s reagent
(0.1% NaCitrate, 0.03% NP40, 0.05 mg/ml propidium iodide, 0.02
mg/ml RNase A), incubated for 15 min at room temperature (RT) in
the dark, and analyzed on a Becton-Dickenson FACS machine
using FloJo analysis software.
BrDU analysis was as follows: cells were incubated with 10 M
BrDU for 45 min, washed, and incubated with 100 mM hydroxyurea
or 0.1 M aphidicolin. S phase cells were followed by FACS analy-
sis of BrDU+ cells at the indicated times using the BrDU flow kit
(BD Pharmingen) according to the manufacturer’s instructions.
Antibodies and Recombinant Proteins
Antibodies were as follows: anti-BID rabbit polyclonal 1:1000
(Wang et al., 1996), anti-BID rabbit polyclonal (Santa Cruz), anti-
ATR rabbit polyclonal 1:1000 (Serotec), anti-phospho BidS61/64
BID rabbit polyclonal 1:500, a kind gift from Drs. Desagher and
Martinou (Desagher et al., 1999); anti-phospho BidS78 BID and
anti-phospho BidS61, rabbit polyclonals, 1:500 (Dr. Atan Gross in
collaboration with Bethyl Laboratories, Inc., Montgomery, Texas);
anti-phospho ATMS1981 1:500 (Rockland), anti-phospho Chk1S345
1:500 (Cell Signaling), Anti-Chk1 1:500 (Santa Cruz), and Anti-Chk2
1:250 (BD Biosciences); anti-MnSOD 1:1000 (Stressgen), and anti-
RAD9 1:250 (Santa Cruz).
S61A BID and S78A BID were obtained using the Quickchange
XL site-directed mutagenesis kit (Stratagene) and cloned into the
BamHI and EcoRI sites of the pBABE retroviral expression vector,
and the NotI/XhoI sites of pOZ-FH-N vector. BIDmIII.2, BIDmIII.3,
and BIDmIII.4 were amplified by PCR from pCDNA3 harboring
these constructs (Wang et al., 1996) and cloned into the BamHI/
EcoRI sites of pBABE puro.
Epitope-tagged BID was generated by cloning the cDNA for BID
into pOZ-FH-C (Nakatani and Ogryzko, 2003) to generate BID that
is tagged at the C terminus with FLAG and HA.
Immunofluorescence
BID-transduced MEFs were treated with DNA-damaging agents (IR
[10 Gy], HU [1mM, 10 mM], Etoposide [20 M, 100 M]) and fixed
with methanol:acetone 3:1. Primary antibodies used were Alexa-
fluor 488-conjugated anti-HA (Molecular Probes), and anti-phos-
pho-H2AX (Upstate). Texas red-conjugated goat anti-rabbit sec-
ondary antibody (Molecular Probes) was used. Where indicated,
cells were incubated for 1 hr with mitotracker red prior to fixation
Cell
590and staining. Staining was visualized using a Zeiss confocal micro-
scope.
Retroviral Transduction
Retroviral supernatants were generated by transient transfection of
the ecotropic packaging cell line 293T with the appropriate expres-
sion plasmid. Tagged BID was introduced into Bid−/− MEFs or
MPCs by retroviral transduction. MPCs were infected by spin inoc-
ulation and cells were selected in puromycin.
In Vitro Kinase Assays
293T cells were transiently transfected with pCDNA3-FLAG ATR
WT or kinase inactive (KI) (K2327R) (Tibbetts et al., 1999) or
pCDNA3-FLAG-ATM WT or KI (Canman et al., 1998) or pCDNA3
vector alone using Fugene 6 reagent. In vitro kinase assays were
performed using standard methods (details in the Supplemental
Experimental Procedures).
Bid Immunoprecipitations
MPCs or MEFs were lysed in TNE buffer, and endogenous mouse
Bid was immunoprecipitated with biotinylated anti-Bid antibody.
Immunoprecipitates were separated on 12% SDS-PAGE and the
phosphorylation status of Bid was monitored using phosphospec-
ific antisera recognizing S61/64, S61, or S78. Total Bid levels were
monitored using an Anti-Bid antibody .
Kinase Inhibitor Treatments
Cells were pretreated with wortmannin (Sigma), LY 294002 (Sigma)
(Vlahos et al., 1994), casein kinase 1 inhibitor CKI-7 (N-[2-aminoe-
thyl]-5-chloro-isoquinoline-8-sulfonamide) (US Biological) (Chijiwa
et al., 1989) or casein kinase 2 inhibitor TBB (4,5,6,7-Tetrabromo-
benzotriazole) (Calbiochem) (Loizou et al., 2004; Sarno et al., 2001,
2002) for 30 min prior to the addition of 10 mM hydroxyurea for 2
hr. Inhibitor concentrations are indicated in the figure legends.
DNA-Damaging Agents
Cells were treated with hydroxyurea (Sigma), mitomycin c (Sigma),
aphidicolin (Sigma), and etoposide (Sigma) as indicated in the fig-
ure legends. Cells were irradiated using a Gammacell 40 or Gam-
macell 100 Cesium 137 source for the doses and times indicated
in the figure legends. Cells were UV irradiated with 10 J/m2 of UV
using a UV Stratalinker 2400 (Stratagene) and harvested following
2 hr of incubation.
Subcellular Fractionation
Subcellular fractionation was performed using a modified Dgnam
protocol. For details, see the Supplemental Experimental Pro-
cedures.
Supplemental Data
Supplemental Data include nine figures and Supplemental Experi-
mental Procedures and can be found with this article online at
http://www.cell.com/cgi/content/full/122/4/579/DC1/.
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